Symbols / XTNT
XTNT Chart
About
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 79.69M |
| Enterprise Value | 101.90M | Income | 1.75M | Sales | 133.08M |
| Book/sh | 0.36 | Cash/sh | 0.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 217 | IPO | — |
| P/E | 56.92 | Forward P/E | 56.92 | PEG | — |
| P/S | 0.60 | P/B | 1.58 | P/C | — |
| EV/EBITDA | 9.35 | EV/Sales | 0.77 | Quick Ratio | 1.01 |
| Current Ratio | 2.21 | Debt/Eq | 64.48 | LT Debt/Eq | — |
| EPS (ttm) | 0.01 | EPS next Y | 0.01 | EPS Growth | — |
| Revenue Growth | 19.00% | Earnings | 2026-03-05 | ROA | 3.87% |
| ROE | 3.64% | ROIC | — | Gross Margin | 62.02% |
| Oper. Margin | 7.64% | Profit Margin | 1.32% | Shs Outstand | 140.00M |
| Shs Float | 54.03M | Short Float | 0.02% | Short Ratio | 0.11 |
| Short Interest | — | 52W High | 0.95 | 52W Low | 0.34 |
| Beta | -0.31 | Avg Volume | 191.74K | Volume | 130.08K |
| Target Price | $1.50 | Recom | None | Prev Close | $0.57 |
| Price | $0.57 | Change | -0.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1.50
Mean price target
2. Current target
$0.57
Latest analyst target
3. DCF / Fair value
$1.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.57
Low
$1.50
High
$1.50
Mean
$1.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-11 | main | BTIG | Buy → Buy | $2 |
| 2024-05-16 | main | BTIG | Buy → Buy | $3 |
| 2023-12-05 | init | BTIG | — → Buy | $2 |
| 2023-07-11 | main | Craig-Hallum | Buy → Buy | $1 |
| 2023-04-26 | init | Craig-Hallum | — → Buy | $1 |
| 2019-05-17 | down | Maxim Group | Buy → Hold | — |
| 2016-12-08 | init | Maxim Group | — → Buy | $2 |
| 2016-11-30 | init | Aegis Capital | — → Buy | $4 |
- Xtant Medical Reports Third Quarter 2025 Financial Results - PR Newswire Mon, 10 Nov 2025 08
- Xtant Medical (NYSE: XTNT) divests Paradigm Spine unit to Companion Spine - Stock Titan Mon, 01 Dec 2025 08
- Earnings call transcript: Xtant Medical Q3 2025 sees earnings beat and stock surge - Investing.com ue, 11 Nov 2025 08
- Xtant Medical Holdings: Micro-cap spine stock tests investor patience as volatility spikes - AD HOC NEWS Wed, 11 Feb 2026 08
- October 2025's Spotlight On Promising Penny Stocks - simplywall.st ue, 14 Oct 2025 07
- How XTNT stock performs during Fed tightening cycles - Weekly Investment Summary & Expert Approved Momentum Trade Ideas - mfd.ru Sun, 15 Feb 2026 13
- Xtant Medical shares change hands in major stock purchase - Investing.com Fri, 11 Apr 2025 07
- Major Stakeholder Sells Massive Shares in Xtant Medical Holdings! - TipRanks Mon, 14 Apr 2025 07
- Is XTNT stock undervalued right now - 2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru Sun, 01 Feb 2026 12
- XTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023 - InvestorPlace Mon, 01 Apr 2024 07
- Xtant Medical announces $15M private placement - MassDevice Mon, 03 Jul 2023 07
- Orbimed advisors sells Xtant Medical stock for $30.7 million - Investing.com Mon, 14 Apr 2025 07
- XTNT Stock Price and Chart — AMEX:XTNT - TradingView hu, 27 Jul 2017 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 158228 | — | — | Stock Award(Grant) at price 0.00 per share. | BAKEWELL JOHN K | Director | — | 2025-11-14 00:00:00 | D |
| 1 | 158228 | — | — | Stock Award(Grant) at price 0.00 per share. | BAKEWELL JOHN K | Director | — | 2025-11-14 00:00:00 | D |
| 2 | 158228 | — | — | Stock Award(Grant) at price 0.00 per share. | LIPSCHULTZ TYLER P | Director | — | 2025-11-14 00:00:00 | D |
| 3 | 553797 | — | — | Stock Award(Grant) at price 0.00 per share. | VIZIRGIANAKIS STAVROS G | Director | — | 2025-11-14 00:00:00 | D |
| 4 | 394937 | — | — | Stock Award(Grant) at price 0.00 per share. | BROWNE SEAN E. | Chief Executive Officer | — | 2025-11-14 00:00:00 | D |
| 5 | 263291 | — | — | Stock Award(Grant) at price 0.00 per share. | NEILS SCOTT C | Chief Financial Officer | — | 2025-11-14 00:00:00 | D |
| 6 | 292253 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHALLENBERGER MARK A. | Chief Operating Officer | — | 2025-11-14 00:00:00 | D |
| 7 | 158228 | — | — | Stock Award(Grant) at price 0.00 per share. | BEESON JONN R. | Director | — | 2025-11-14 00:00:00 | D |
| 8 | 158228 | — | — | Stock Award(Grant) at price 0.00 per share. | JAIN ABHINAV | Director | — | 2025-11-14 00:00:00 | D |
| 9 | 73114592 | 30708129 | — | Sale at price 0.42 per share. | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-10 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.05K | 2.51M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -7.88M | -6.88M | -5.43M | -2.52M |
| TotalUnusualItems | 5.00K | 11.96M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 5.00K | 11.96M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.45M | 660.00K | -8.48M | -4.85M |
| ReconciledDepreciation | 4.22M | 3.17M | 1.29M | 1.33M |
| ReconciledCostOfRevenue | 49.05M | 35.84M | 25.83M | 22.77M |
| EBITDA | -7.88M | 5.08M | -5.43M | -2.52M |
| EBIT | -12.10M | 1.90M | -6.72M | -3.85M |
| NetInterestIncome | -4.16M | -2.79M | -1.66M | -995.00K |
| InterestExpense | 4.16M | 2.94M | 1.69M | 995.00K |
| InterestIncome | 0.00 | 149.00K | 31.00K | 0.00 |
| NormalizedIncome | -16.45M | -8.79M | -8.48M | -4.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.45M | 660.00K | -8.48M | -4.85M |
| TotalExpenses | 129.34M | 101.46M | 64.72M | 59.12M |
| TotalOperatingIncomeAsReported | -12.07M | -10.16M | -6.75M | -3.85M |
| DilutedAverageShares | 133.67M | 126.79M | 94.09M | 85.46M |
| BasicAverageShares | 133.67M | 119.09M | 94.09M | 85.46M |
| DilutedEPS | -0.12 | 0.01 | -0.09 | -0.06 |
| BasicEPS | -0.12 | 0.01 | -0.09 | -0.06 |
| DilutedNIAvailtoComStockholders | -16.45M | 660.00K | -8.48M | -4.85M |
| NetIncomeCommonStockholders | -16.45M | 660.00K | -8.48M | -4.85M |
| NetIncome | -16.45M | 660.00K | -8.48M | -4.85M |
| NetIncomeIncludingNoncontrollingInterests | -16.45M | 660.00K | -8.48M | -4.85M |
| NetIncomeContinuousOperations | -16.45M | 660.00K | -8.48M | -4.85M |
| TaxProvision | 187.00K | -1.70M | 69.00K | 0.00 |
| PretaxIncome | -16.26M | -1.04M | -8.42M | -4.85M |
| OtherIncomeExpense | -28.00K | 11.91M | ||
| OtherNonOperatingIncomeExpenses | -33.00K | -49.00K | ||
| SpecialIncomeCharges | 0.00 | 11.69M | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | -11.69M | 0.00 | |
| GainOnSaleOfSecurity | 5.00K | 265.00K | ||
| NetNonOperatingInterestIncomeExpense | -4.16M | -2.79M | -1.66M | -995.00K |
| InterestExpenseNonOperating | 4.16M | 2.94M | 1.69M | 995.00K |
| InterestIncomeNonOperating | 0.00 | 149.00K | 31.00K | 0.00 |
| OperatingIncome | -12.07M | -10.16M | -6.75M | -3.85M |
| OperatingExpense | 80.29M | 65.62M | 38.89M | 36.34M |
| ResearchAndDevelopment | 2.38M | 1.34M | 915.00K | 870.00K |
| SellingGeneralAndAdministration | 77.91M | 64.29M | 37.98M | 35.47M |
| SellingAndMarketingExpense | 49.21M | 38.44M | 22.52M | 21.02M |
| GeneralAndAdministrativeExpense | 28.69M | 25.85M | 15.46M | 14.45M |
| OtherGandA | 28.69M | 25.85M | 15.46M | 14.45M |
| GrossProfit | 68.22M | 55.47M | 32.14M | 32.49M |
| CostOfRevenue | 49.05M | 35.84M | 25.83M | 22.77M |
| TotalRevenue | 117.27M | 91.30M | 57.97M | 55.26M |
| OperatingRevenue | 117.27M | 91.30M | 57.97M | 55.15M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 139.05M | 130.18M | 108.87M | 87.07M |
| ShareIssued | 139.05M | 130.18M | 108.87M | 87.07M |
| NetDebt | 27.96M | 16.07M | ||
| TotalDebt | 35.14M | 23.56M | 17.07M | 16.84M |
| TangibleBookValue | 27.30M | 33.96M | 30.62M | 27.28M |
| InvestedCapital | 77.12M | 73.14M | 49.57M | 46.29M |
| WorkingCapital | 38.53M | 41.88M | 34.10M | 33.25M |
| NetTangibleAssets | 27.30M | 33.96M | 30.62M | 27.28M |
| CapitalLeaseObligations | 985.00K | 1.77M | 1.67M | 1.44M |
| CommonStockEquity | 42.96M | 51.35M | 34.17M | 30.88M |
| TotalCapitalization | 65.00M | 68.52M | 43.86M | 42.67M |
| TotalEquityGrossMinorityInterest | 42.96M | 51.35M | 34.17M | 30.88M |
| StockholdersEquity | 42.96M | 51.35M | 34.17M | 30.88M |
| GainsLossesNotAffectingRetainedEarnings | -316.00K | 29.00K | 0.00 | |
| OtherEquityAdjustments | -316.00K | 29.00K | ||
| RetainedEarnings | -259.46M | -243.01M | -243.67M | -235.19M |
| AdditionalPaidInCapital | 302.74M | 294.33M | 277.84M | 266.07M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.87M | 41.26M | 26.06M | 23.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 22.29M | 18.27M | 10.84M | 12.73M |
| NonCurrentAccruedExpenses | 0.00 | 210.00K | 0.00 | |
| NonCurrentDeferredLiabilities | 42.00K | 21.00K | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 42.00K | 21.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 22.25M | 18.04M | 10.84M | 12.73M |
| LongTermCapitalLeaseObligation | 213.00K | 875.00K | 1.15M | 945.00K |
| LongTermDebt | 22.04M | 17.17M | 9.69M | 11.79M |
| CurrentLiabilities | 28.58M | 22.99M | 15.22M | 11.08M |
| CurrentDebtAndCapitalLeaseObligation | 12.89M | 5.52M | 6.23M | 4.11M |
| CurrentCapitalLeaseObligation | 772.00K | 895.00K | 520.00K | 493.00K |
| CurrentDebt | 12.12M | 4.62M | 5.71M | 3.62M |
| OtherCurrentBorrowings | 2.33M | |||
| LineOfCredit | 12.12M | 4.62M | 3.38M | 3.62M |
| PayablesAndAccruedExpenses | 15.69M | 17.47M | 8.99M | 6.96M |
| CurrentAccruedExpenses | 2.21M | 1.53M | 1.03M | 1.17M |
| Payables | 13.48M | 15.94M | 7.95M | 5.80M |
| OtherPayable | 5.57M | 8.89M | 4.46M | 3.18M |
| AccountsPayable | 7.92M | 7.05M | 3.49M | 2.62M |
| TotalAssets | 93.84M | 92.61M | 60.23M | 54.69M |
| TotalNonCurrentAssets | 26.72M | 27.74M | 10.91M | 10.36M |
| OtherNonCurrentAssets | 103.00K | 141.00K | 197.00K | 287.00K |
| GoodwillAndOtherIntangibleAssets | 15.66M | 17.39M | 3.55M | 3.60M |
| OtherIntangibleAssets | 8.36M | 10.09M | 344.00K | 400.00K |
| Goodwill | 7.30M | 7.30M | 3.21M | 3.21M |
| NetPPE | 10.96M | 10.21M | 7.17M | 6.47M |
| AccumulatedDepreciation | -19.84M | -19.68M | -17.96M | -17.17M |
| GrossPPE | 30.80M | 29.89M | 25.13M | 23.64M |
| Leases | 4.36M | 4.35M | 4.11M | 3.85M |
| OtherProperties | 24.83M | 23.99M | 19.75M | 18.55M |
| MachineryFurnitureEquipment | 1.61M | 1.56M | 1.27M | 1.24M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 67.12M | 64.87M | 49.32M | 44.33M |
| OtherCurrentAssets | 1.60M | 1.33M | 673.00K | 844.00K |
| RestrictedCash | 22.00K | 208.00K | 209.00K | 144.00K |
| PrepaidAssets | 844.00K | |||
| Inventory | 38.63M | 36.88M | 17.29M | 17.95M |
| FinishedGoods | 29.20M | 28.05M | 10.86M | 11.76M |
| WorkInProcess | 2.81M | 1.56M | 798.00K | 571.00K |
| RawMaterials | 6.62M | 7.27M | 5.63M | 5.61M |
| Receivables | 20.66M | 20.73M | 10.85M | 7.15M |
| AccountsReceivable | 20.66M | 20.73M | 10.85M | 7.15M |
| AllowanceForDoubtfulAccountsReceivable | -1.44M | -920.00K | -515.00K | -552.00K |
| GrossAccountsReceivable | 22.10M | 21.65M | 11.37M | 7.71M |
| CashCashEquivalentsAndShortTermInvestments | 6.20M | 5.71M | 20.30M | 18.24M |
| CashAndCashEquivalents | 6.20M | 5.71M | 20.30M | 18.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.01M | -10.97M | -7.11M | -1.68M |
| RepaymentOfDebt | -105.21M | -77.04M | -54.52M | -36.95M |
| IssuanceOfDebt | 117.64M | 83.22M | 54.23M | 36.36M |
| IssuanceOfCapitalStock | 4.46M | 14.01M | 9.31M | 18.43M |
| CapitalExpenditure | -4.11M | -1.46M | -1.76M | -2.12M |
| InterestPaidSupplementalData | 3.64M | 2.55M | 1.45M | 846.00K |
| EndCashPosition | 6.22M | 5.92M | 20.51M | 18.39M |
| BeginningCashPosition | 5.92M | 20.51M | 18.39M | 2.34M |
| EffectOfExchangeRateChanges | -149.00K | 24.00K | 0.00 | |
| ChangesInCash | 447.00K | -14.61M | 2.12M | 16.05M |
| FinancingCashFlow | 16.07M | 19.69M | 9.02M | 17.50M |
| CashFlowFromContinuingFinancingActivities | 16.07M | 19.69M | 9.02M | 17.50M |
| NetOtherFinancingCharges | -829.00K | -500.00K | -337.00K | |
| ProceedsFromStockOptionExercised | 13.00K | 0.00 | 0.00 | |
| NetCommonStockIssuance | 4.46M | 14.01M | 9.31M | 18.43M |
| CommonStockIssuance | 4.46M | 14.01M | 9.31M | 18.43M |
| NetIssuancePaymentsOfDebt | 12.43M | 6.18M | -291.00K | -592.00K |
| NetShortTermDebtIssuance | 7.50M | 1.24M | -241.00K | -131.00K |
| ShortTermDebtPayments | -105.14M | -76.98M | -54.47M | -36.49M |
| ShortTermDebtIssuance | 112.64M | 78.22M | 54.23M | 36.36M |
| NetLongTermDebtIssuance | 4.93M | 4.94M | -50.00K | -461.00K |
| LongTermDebtPayments | -65.00K | -63.00K | -50.00K | -461.00K |
| LongTermDebtIssuance | 5.00M | 5.00M | 0.00 | |
| InvestingCashFlow | -3.73M | -24.78M | -1.56M | -1.89M |
| CashFlowFromContinuingInvestingActivities | -3.73M | -24.78M | -1.56M | -1.89M |
| NetBusinessPurchaseAndSale | 0.00 | -23.50M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -23.50M | 0.00 | |
| NetPPEPurchaseAndSale | -3.73M | -1.28M | -1.56M | -1.89M |
| SaleOfPPE | 383.00K | 175.00K | 205.00K | 225.00K |
| PurchaseOfPPE | -4.11M | -1.46M | -1.76M | -2.12M |
| OperatingCashFlow | -11.90M | -9.52M | -5.34M | 439.00K |
| CashFlowFromContinuingOperatingActivities | -11.90M | -9.52M | -5.34M | 439.00K |
| ChangeInWorkingCapital | -5.35M | -3.63M | -2.81M | 793.00K |
| ChangeInPayablesAndAccruedExpense | -1.88M | 6.77M | 2.02M | -1.45M |
| ChangeInAccruedExpense | -2.92M | 3.79M | 1.15M | -1.11M |
| ChangeInPayable | 1.03M | 2.98M | 875.00K | -332.00K |
| ChangeInAccountPayable | 1.03M | 2.98M | 875.00K | -332.00K |
| ChangeInPrepaidAssets | -218.00K | 220.00K | 261.00K | -67.00K |
| ChangeInInventory | -2.49M | -1.89M | -1.15M | 2.62M |
| ChangeInReceivables | -755.00K | -8.74M | -3.94M | -319.00K |
| ChangesInAccountReceivables | -755.00K | -8.74M | -3.94M | -319.00K |
| OtherNonCashItems | 496.00K | -11.29M | 237.00K | 156.00K |
| StockBasedCompensation | 4.12M | 2.74M | 2.46M | 2.21M |
| ProvisionandWriteOffofAssets | 1.31M | 854.00K | 2.06M | 884.00K |
| DeferredTax | 21.00K | -1.90M | 0.00 | |
| DeferredIncomeTax | 21.00K | -1.90M | 0.00 | |
| DepreciationAmortizationDepletion | 4.22M | 3.17M | 1.29M | 1.33M |
| DepreciationAndAmortization | 4.22M | 3.17M | 1.29M | 1.33M |
| OperatingGainsLosses | -264.00K | -115.00K | -93.00K | -86.00K |
| GainLossOnSaleOfPPE | -264.00K | -115.00K | -93.00K | -86.00K |
| NetIncomeFromContinuingOperations | -16.45M | 660.00K | -8.48M | -4.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XTNT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|